Category Archives: Cell Therapy

The Alliance for the Advancement of Adult Stem Cell Therapy and Research
Billy Orr is a quadriplegic who spent the last quarter century in a wheelchair. You are watching Billy Orr stand and walk for the first time after having adu...

By: TheStemCellAlliance

View original post here:
The Alliance for the Advancement of Adult Stem Cell Therapy and Research - Video

MOUNTAIN VIEW, Calif., June 10, 2013 /PRNewswire/ -- SanBio Inc., a California-based regenerative medicine company, announced today that the U.S. Food and Drug Administration has approved their Investigational New Drug application (IND) for the use of SB623, a novel allogeneic stem cell therapy product, in patients suffering from traumatic brain injuries (TBI's). This approval allows the company to proceed with a Phase 1/2a clinical trial testing the safety and feasibility of the therapy. The clinical trial is expected to be carried out at several major hospitals in the United States.

"This is the second clinical program for SanBio," said Keita Mori, SanBio's Chief Executive Officer, "we see this as a clear validation of our development program and a significant broadening of the therapeutic application of our lead product SB623 for the treatment of unaddressed chronic neurological deficits."

"We measure the responses of TBI patients to physical therapy every day. Progress is often painfully slow and incremental," said Dr. Daniel Lu, Principal Investigator, Neuroplasticity and Repair Laboratory and Director, Neuromotor Recovery Research Center, University of California, Los Angeles, "If this new cell therapy approach improves outcomes it could have a dramatic positive effect on many lives."

About Traumatic Brain Injury: According to the Center for Disease Control and Prevention, more the 1.7 million people in the United States sustain a traumatic brain injury each year, resulting in approximately 50,000 deaths and 275,000 hospitalizations. Many of these more severely injured patients suffer permanent disabilities, including loss of motor function and cognitive impairment. Other than physical rehabilitation there is no effective therapy. Direct medical costs and indirect costs such as lost productivity of TBI totaled an estimated $76.5 billion in the United States in 2000.

About SB623: SB623 is a proprietary cell therapy product consisting of cells derived from genetically modified bone marrow stromal cells obtained from healthy adult donors. SB623 is administered adjacent to the damaged area of the brain. SB623 functions by producing factors that aid the regenerative process.

About SanBio: SanBio is a privately held San Francisco Bay Area biotechnology company focused on the discovery and development of new regenerative cell therapy products.

For more information: http://www.san-bio.com

Read more from the original source:
SanBio Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product ...

Sugar 1week post stem cell therapy

By: Tim O #39;Neill, DVM

See original here:
Sugar 1week post stem cell therapy - Video

VANCEBURG | A Lewis County man is working his way toward stem cell therapy in an attempt to help him walk again.

Jennifer Richardson, a long-time friend of Anthony Schumacher, said Schumacher was involved in an accident in December 2012, which left him paralyzed.

According to Richardson, Schumacher was in a comma for a few days and has no memory of the accident.

"He was going to work when his tire blew out and he wrecked the car," Richardson said. "He was in a coma for days and when he woke up he was paralyzed from the belly button down and couldn't remember anything."

Tammy Moore, Schumacher's mother, said he keeps a positive attitude about his situation.

"He's a happy person," she said. "He works out everyday and tries to learn new things about his situation and the procedure."

Moore said she would like to see Schumacher get the therapy.

"I don't know a lot about it. I'm still learning about it," she said. "But, from what I've seen, it's a good thing that can help him get at least some of the feeling back, if not all. I want to see him get it, if it can help."

Schumacher said he looks forward to the possibility of the procedure, too.

"I'm hopeful," he said. "I want to get it done. I've been trying to do my research and I would like to do this."

Read the original here:
Lewis County man hopes for stem cell therapy

Washington, June 7 (IANS) Researchers have shown that cell therapy may be used in liver disease to regenerate liver cells, says a study.

Investigators discovered that a human embryonic stem cell can be differentiated into a previously unknown liver progenitor cell, an early offspring of a stem cell, and produce mature and functional liver cells, reports Science Daily.

"The discovery of the novel progenitor represents a fundamental advance in this field and potentially to the liver regeneration field using cell therapy," said the study's senior author, Valerie Gouon-Evans, PharmD, Ph.D., assistant professor in the Department of Developmental and Regenerative Biology, Black Family Stem Cell Institute, at the Icahn School of Medicine at Mount Sinai.

"Until now, liver transplantation has been the most successful treatment for people with liver failure, but we have a drastic shortage of organs. This discovery may help circumvent that problem."

The study has been published in the journal Cell Stem Cell Friday.

Read the rest here:
Cell therapy may regenerate liver cells

BOULDER CREEK -- Growing up, Jerry MacCallister wanted to be a naval aviator. Now, he simply wants to scratch his own nose.

The 23-year-old Boulder Creek resident broke his neck in a 2009 dirt biking accident, leaving him paralyzed from the neck down. While he regained some mobility in his arms during his initial six-week hospital stay, he lost it all in 2012 when he fell into a coma for eight days. Since then, he's slowly relearned how to breathe and talk, but still can't move his body.

After years of working with countless doctors and physical therapists without seeing significant improvement, MacCallister will undergo stem cell therapy this summer in Thailand. Looking to chip away at $40,000 in travel and medical procedures, his family's hosting a spaghetti feed Saturday at the Boulder Creek Fire Department.

"It's basically his last hope," said his mother, Katie MacCallister.

Her son will receive eight stem cell injections derived from an umbilical cord during the course of 40 days, as well as physical, aquatic and occupational therapy and acupuncture. It typically takes up to nine months to see results.

Beike Biotechnology, a company that specializes in adult stem cell therapy, will oversee the treatment.

"Realistically, nobody expects him to get up and walk away from (this therapy,) but we want him to scratch his own itches and feed himself," said Katie MacCallister, who has researched the treatment since 2009.

When

After the coma, Jerry MacCallister would wake up each morning, forgetting that he was paralyzed -- every day for months he had to relearn that he couldn't move. He spent 10 weeks in the hospital.

"It's every mother's worst nightmare," Katie MacCallister said as she choked back tears. "I wouldn't wish it on my own worst enemy."

Go here to read the rest:
Boulder Creek family of quadriplegic raises money for stem cell therapy

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/cn2vq9/cell_therapy) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering.

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The cell-based markets was analyzed for 2012, and projected to 2022. The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 289 of these are profiled in part II of the report along with tabulation of 278 alliances. Of these companies, 160 are involved in stem cells. Profiles of 72 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 55 Tables and 12 Figures. The bibliography contains 1,050 selected references, which are cited in the text.

Key Topics Covered:

Originally posted here:
Research and Markets: Cell Therapy - Technologies, Markets and Companies - Updated 2013-2022 Global Report